Avadel Pharmaceuticals (AVDL) Attracts Institutional Investment

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is among the fastest growing small cap stocks to buy. As disclosed in the latest Form 13F filing with the SEC, Nuveen LLC has increased its position in Avadel Pharmaceuticals plc (NASDAQ:AVDL) through the purchase of 517,939 shares, worth $4,055,000, during the first quarter. The investment leader now owns about 0.54% of the company.

During its recent earnings call, the management highlighted the growth momentum of LUMRYZ, the company’s lead product, which is anticipated to drive the future of Avadel Pharmaceuticals plc (NASDAQ:AVDL). As Thomas S. McHugh, the senior VP, stated,

“We believe we have clear visibility to deliver on the updated guidance, which is based on the favorable trends in the first half of 2025, including growing patient demand and improvements in key patient metrics.”

The company’s commercial strength, together with investments in HCP and patient-centered programs, can’t be overlooked. Even if we consider the comparative statistics, the year-to-date return delivered by AVDL stands at 40.44% in contrast to the S&P 500 (^GSPC)’s return of a mere 9.84%. With key metrics aligning with the growth narrative, Avadel Pharmaceuticals plc (NASDAQ: AVDL) is expected not only to sustain, but also to thrive.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is an Ireland-based biopharmaceutical company that mainly offers LUMRYZ to treat cataplexy or excessive daytime sleepiness. Incorporated in 2015, the company is dedicated to addressing unmet medical needs.

While we acknowledge the potential of AVDL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.